For the year ending 2025-12-31, BSX had $1,541M increase in cash & cash equivalents over the period. $3,658M in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net income (loss) | 2,892 | 1,846 | 1,592 | 698 |
| Loss (gain) on disposal of businesses and assets | - | 0 | 0 | -22 |
| Depreciation and amortization | 1,368 | 1,269 | 1,196 | 1,136 |
| Deferred and prepaid income taxes | -2 | -70 | -1 | -63 |
| Stock-based compensation expense | 299 | 266 | 233 | 220 |
| Goodwill and other intangible asset impairment charges | 46 | 386 | 58 | 132 |
| Net loss (gain) on investments and notes receivable | 139 | -79 | -59 | -1 |
| Contingent consideration net expense (benefit) | 18 | -5 | 58 | 35 |
| Inventory step-up amortization | 132 | 51 | 6 | 32 |
| Debt extinguishment costs | - | - | - | -194 |
| Debt extinguishment net charges | - | 0 | 0 | - |
| Fixed asset and right-of-use asset impairment | 124 | - | - | - |
| Other, net | 42 | 74 | 73 | 125 |
| Trade accounts receivable | 269 | 351 | 238 | 220 |
| Inventories | 188 | 228 | 660 | 321 |
| Other assets | 85 | 126 | -10 | 209 |
| Accounts payable, accrued expenses and other liabilities | 296 | 243 | 118 | -255 |
| Cash provided by (used for) operating activities | 4,534 | 3,435 | 2,503 | 1,526 |
| Purchases of property, plant and equipment and internal use software | 876 | 790 | 711 | 588 |
| Proceeds from sale of property, plant and equipment | - | 3 | 4 | 12 |
| Payments for acquisitions of businesses, net of cash acquired | 1,593 | 4,640 | 1,811 | 1,542 |
| Payments for investments and acquisitions of certain technologies | 254 | 280 | 89 | 24 |
| Proceeds from disposal of certain businesses and assets | - | 0 | 0 | 5 |
| Other, net | -84 | -20 | -30 | -70 |
| Proceeds from settlements of hedge contracts | - | 0 | -2 | -56 |
| Cash provided by (used for) investing activities | -2,640 | -5,687 | -2,574 | -2,011 |
| Payment of contingent consideration previously established in purchase accounting | 62 | 131 | 39 | 335 |
| Payments for royalty rights | - | 26 | 50 | 75 |
| Payments for finance leases | 258 | 25 | - | - |
| Payments on short-term borrowings | 1,595 | 504 | 0 | 250 |
| Proceeds from short-term borrowings, net of debt issuance costs | - | 24 | - | 0 |
| Net increase (decrease) in commercial paper | -196 | 187 | -4 | -1 |
| Payments on borrowings from credit facilities | - | - | - | 0 |
| Proceeds from borrowings on credit facilities | - | - | - | 0 |
| Payments on long-term borrowings and debt extinguishment costs | - | 0 | 0 | 3,184 |
| Proceeds from long-term borrowings, net of debt issuance costs | 1,558 | 2,145 | 0 | 3,270 |
| Cash dividends paid on preferred stock | - | 0 | 28 | 55 |
| Net proceeds from issuance of preferred stock in connection with public offering | - | - | - | 0 |
| Net proceeds from issuance of common stock in connection with public offering | - | - | - | 0 |
| Payments for repurchase of common stock | - | - | - | 0 |
| Cash used to net share settle employee equity awards | 131 | 87 | 56 | 53 |
| Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans | 282 | 230 | 182 | 136 |
| Other, net | 7 | - | - | - |
| Cash provided by (used for) financing activities | -395 | 1,814 | 5 | -548 |
| Effect of foreign exchange rates on cash | 42 | -11 | -4 | -9 |
| Net increase (decrease)in cash, cash equivalents, restricted cash and restricted cash equivalents | 1,541 | -450 | -70 | -1,042 |
| Cash and cash equivalents at beginning of period | 606 | 1,055 | 1,126 | 2,168 |
| Cash and cash equivalents at end of period | 2,147 | 606 | 1,055 | 1,126 |
BOSTON SCIENTIFIC CORP (BSX)
BOSTON SCIENTIFIC CORP (BSX)